CL2014002822A1 - Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v. - Google Patents

Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v.

Info

Publication number: CL2014002822A1
Authority: CL; Chile
Prior art keywords: chylomicrenia; syndrome; type; hyperlipoproteinemia; familial
Prior art date: 2012-04-27

Application number

CL2014002822A

Other languages

English (en)

Inventor

Zecri Frédéric

Chen Xin

Ding Yiping

Duvadie Rohit

Gai Yu

Harrison Tyler

Liu Qian

Larrow Jay

Yik Ching Mao Justin

Patel Sejal

Ye Jiong

Zheng Xuchun

Zheng Rui

Zhou Yizong

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2014-10-20

Publication date

2015-04-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002822(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-20 Application filed by Novartis Ag filed Critical Novartis Ag

2015-04-24 Publication of CL2014002822A1 publication Critical patent/CL2014002822A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2014002822A 2012-04-27 2014-10-20 Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v. CL2014002822A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261639341P	2012-04-27	2012-04-27
US201361787695P	2013-03-15	2013-03-15
CN2013072735		2013-03-15

Publications (1)

Publication Number	Publication Date
CL2014002822A1 true CL2014002822A1 (es)	2015-04-24

Family

ID=48577190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002822A CL2014002822A1 (es)	2012-04-27	2014-10-20	Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v.

Country Status (26)

Country	Link
US (2)	US8993619B2 (es)
EP (1)	EP2852590B1 (es)
JP (1)	JP6042529B2 (es)
KR (1)	KR20150013194A (es)
CN (1)	CN104395309B (es)
AP (1)	AP3592A (es)
AR (1)	AR090859A1 (es)
AU (1)	AU2013254307B2 (es)
BR (1)	BR112014026760A8 (es)
CA (1)	CA2870336A1 (es)
CL (1)	CL2014002822A1 (es)
CO (1)	CO7111275A2 (es)
CR (1)	CR20140494A (es)
EA (1)	EA025050B1 (es)
EC (1)	ECSP14030538A (es)
ES (1)	ES2624291T3 (es)
IL (1)	IL235313A0 (es)
MA (1)	MA37439B1 (es)
MX (1)	MX357768B (es)
PE (2)	PE20150724A1 (es)
PH (1)	PH12014502413A1 (es)
SG (1)	SG11201406526WA (es)
TN (1)	TN2014000425A1 (es)
TW (1)	TW201348239A (es)
UY (1)	UY34767A (es)
WO (1)	WO2013160873A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3632919T (lt)	2012-04-26	2023-02-27	Bristol-Myers Squibb Company	Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (en)	2013-01-14	2014-07-17	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en)	2013-01-15	2017-08-30	Incyte Corp	Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US8962660B2 (en) *	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
CA2921959A1 (en)	2013-08-23	2015-02-26	Incyte Corporation	Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en)	2014-07-14	2016-01-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN104292189B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法
CN104292190B (zh) *	2014-09-03	2016-05-04	哈尔滨工业大学	一种β-溴代四氢呋喃类化合物的合成方法
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es)	2015-09-09	2017-11-29	Incyte Corp	Sales de un inhibidor de pim quinasa
TW201718546A (zh)	2015-10-02	2017-06-01	英塞特公司	適用作pim激酶抑制劑之雜環化合物
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US20210317131A1 (en) *	2018-09-18	2021-10-14	Bristol-Myers Squibb Company	Oxabicyclo acids as lpa antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200303742A (en)	2001-11-21	2003-09-16	Novartis Ag	Organic compounds
CA2514733A1 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
RU2374241C2 (ru)	2003-05-20	2009-11-27	Новартис Аг	N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
DE602005022089D1 (de) *	2004-08-06	2010-08-12	Merck Sharp & Dohme	Sulfonylverbindungen als hemmer von 11-beta-hydroxysteroiddehydrogenase-1
UA97474C2 (ru) *	2006-03-31	2012-02-27	Новартис Аг	Соединения для лечения нарушений, связанных с активностью dgat1
KR20100099738A (ko) *	2007-12-20	2010-09-13	아스트라제네카 아베	Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
EP2781516B1 (en) *	2010-10-07	2016-12-07	Novartis AG	New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid
US8962660B2 (en) *	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators

2013
- 2013-04-25 KR KR1020147032910A patent/KR20150013194A/ko not_active Application Discontinuation
- 2013-04-25 EP EP13727385.0A patent/EP2852590B1/en not_active Not-in-force
- 2013-04-25 MA MA37439A patent/MA37439B1/fr unknown
- 2013-04-25 PE PE2014001902A patent/PE20150724A1/es not_active Application Discontinuation
- 2013-04-25 AU AU2013254307A patent/AU2013254307B2/en not_active Ceased
- 2013-04-25 WO PCT/IB2013/053292 patent/WO2013160873A1/en active Application Filing
- 2013-04-25 JP JP2015507656A patent/JP6042529B2/ja not_active Expired - Fee Related
- 2013-04-25 CN CN201380034256.8A patent/CN104395309B/zh not_active Expired - Fee Related
- 2013-04-25 ES ES13727385.0T patent/ES2624291T3/es active Active
- 2013-04-25 AP AP2014008018A patent/AP3592A/xx active
- 2013-04-25 MX MX2014013002A patent/MX357768B/es active IP Right Grant
- 2013-04-25 BR BR112014026760A patent/BR112014026760A8/pt not_active Application Discontinuation
- 2013-04-25 SG SG11201406526WA patent/SG11201406526WA/en unknown
- 2013-04-25 CA CA2870336A patent/CA2870336A1/en not_active Abandoned
- 2013-04-25 PE PE2016000359A patent/PE20160802A1/es not_active Application Discontinuation
- 2013-04-25 EA EA201491970A patent/EA025050B1/ru not_active IP Right Cessation
- 2013-04-26 TW TW102115141A patent/TW201348239A/zh unknown
- 2013-04-26 UY UY0001034767A patent/UY34767A/es not_active Application Discontinuation
- 2013-04-26 AR ARP130101409A patent/AR090859A1/es unknown
- 2013-04-26 US US13/871,586 patent/US8993619B2/en not_active Expired - Fee Related
2014
- 2014-10-13 TN TN2014000425A patent/TN2014000425A1/fr unknown
- 2014-10-20 CL CL2014002822A patent/CL2014002822A1/es unknown
- 2014-10-23 IL IL235313A patent/IL235313A0/en unknown
- 2014-10-27 PH PH12014502413A patent/PH12014502413A1/en unknown
- 2014-10-27 CO CO14237492A patent/CO7111275A2/es active IP Right Grant
- 2014-10-27 CR CR20140494A patent/CR20140494A/es unknown
- 2014-11-27 EC ECIEPI201430538A patent/ECSP14030538A/es unknown
2015
- 2015-02-20 US US14/628,205 patent/US20150166563A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20150724A1 (es)	2015-05-17
CN104395309B (zh)	2016-09-28
UY34767A (es)	2013-11-29
AU2013254307A1 (en)	2014-10-30
EA025050B1 (ru)	2016-11-30
TW201348239A (zh)	2013-12-01
MX2014013002A (es)	2015-01-22
US8993619B2 (en)	2015-03-31
IL235313A0 (en)	2014-12-31
MA37439A1 (fr)	2016-07-29
WO2013160873A1 (en)	2013-10-31
ECSP14030538A (es)	2015-11-30
MA37439B1 (fr)	2017-02-28
MX357768B (es)	2018-07-24
ES2624291T3 (es)	2017-07-13
BR112014026760A8 (pt)	2018-01-16
EP2852590A1 (en)	2015-04-01
CA2870336A1 (en)	2013-10-31
EA201491970A1 (ru)	2015-03-31
AR090859A1 (es)	2014-12-10
BR112014026760A2 (pt)	2017-06-27
PE20160802A1 (es)	2016-09-03
PH12014502413A1 (en)	2015-01-12
JP6042529B2 (ja)	2016-12-14
SG11201406526WA (en)	2014-11-27
TN2014000425A1 (en)	2016-03-30
EP2852590B1 (en)	2017-02-01
AP3592A (en)	2016-02-15
CO7111275A2 (es)	2014-11-10
AP2014008018A0 (en)	2014-10-31
CN104395309A (zh)	2015-03-04
JP2015514798A (ja)	2015-05-21
CR20140494A (es)	2015-03-13
KR20150013194A (ko)	2015-02-04
AU2013254307B2 (en)	2016-05-26
US20150166563A1 (en)	2015-06-18
US20130289058A1 (en)	2013-10-31

Publication	Publication Date	Title
CL2014002822A1 (es)	2015-04-24	Compuestos derivados de acido oxabiciclo-[2.2.2]-sustituido acetico, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; uso para la prevencion, demora del progreso o el tratamiento del virus de hepatitis c, diabetes tipo ii, sindrome de quilomicrenia, sindrome de quilomicrenia familiar e hiperlipoproteinemia tipo v.
CL2014000311A1 (es)	2014-10-17	Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014003168A1 (es)	2015-05-22	Compuestos derivados de tetrahidrofurano o tetrahidrotiofeno teniendo un resto d-aminoacido; composicion farmaceutica que los comprende, util para el tratamiento de un huesped infectado con el virus de la hepatitis c.
CL2013001141A1 (es)	2013-10-04	Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2015001699A1 (es)	2015-10-30	Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
BR112014021531A2 (pt)	2017-06-20	composto, composição farmacêutica e usos dos mesmos
CL2015000487A1 (es)	2015-06-12	Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2015001279A1 (es)	2015-06-26	Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015001733A1 (es)	2015-10-23	Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CL2013001339A1 (es)	2014-03-07	Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
CL2015000482A1 (es)	2015-07-10	Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
EA201791916A1 (ru)	2018-07-31	2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CL2014000398A1 (es)	2014-08-01	Compuestos derivados de aminoquinazolinas, inhibidores de quinasa: composicion farmaceutica; y su uso para el tratamiento de uveitis, sindrome febril, dermatitis, diabetes mellitus tipo 2, artritis reumatoide, colitis ulcerativa.
CL2014002100A1 (es)	2015-10-23	Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal.
BR112014010179A2 (pt)	2017-04-25	composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
CL2013001600A1 (es)	2013-10-25	Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
CL2014002257A1 (es)	2014-12-05	Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2014000543A1 (es)	2014-09-26	Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112014010183A2 (pt)	2017-05-02	composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase